Checkpoint Trends Ltd Stock Price Today (NSE: CHECKPOINT)
Fundamental Score
Checkpoint Trends Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Checkpoint Trends Ltd share price today is ₹33.46, up +0.00% on NSE/BSE as of 1 August 2026. Checkpoint Trends Ltd (CHECKPOINT) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹19.83 (Cr). The 52-week high for CHECKPOINT share price is ₹144.40 and the 52-week low is ₹28.22. At a P/E ratio of 13.13x, CHECKPOINT is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 12.69% and a debt-to-equity ratio of 0.29.
Checkpoint Trends Ltd Share Price Chart — NSE/BSE Historical Performance
Checkpoint Trends Ltd share price chart: -8.18% return over the past month. 52-week high ₹144.40, 52-week low ₹28.22.
Checkpoint Trends Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹32.00 | ₹35.97 | ₹32.00 | ₹33.46 | 1.64K (Cr) | |
| ₹35.00 | ₹35.87 | ₹33.10 | ₹33.45 | 2.34K (Cr) | |
| ₹37.18 | ₹38.95 | ₹35.60 | ₹36.26 | 11.14K (Cr) | |
| ₹39.55 | ₹39.55 | ₹39.55 | ₹39.55 | 0.00 (Cr) | |
| ₹37.01 | ₹39.56 | ₹37.01 | ₹39.55 | 1.38K (Cr) | |
| ₹40.20 | ₹40.20 | ₹37.00 | ₹39.56 | 1.43K (Cr) | |
| ₹42.00 | ₹42.00 | ₹36.58 | ₹36.72 | 716.00 (Cr) | |
| ₹38.98 | ₹42.00 | ₹37.51 | ₹38.20 | 75.00 (Cr) | |
| ₹38.00 | ₹40.00 | ₹37.01 | ₹39.46 | 1.03K (Cr) | |
| ₹37.51 | ₹41.00 | ₹36.13 | ₹37.95 | 2.06K (Cr) |
Checkpoint Trends Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹39.93 | ₹42.50 | ₹32.00 | ₹33.46 | -16.20% | |
| ₹44.20 | ₹47.50 | ₹35.41 | ₹38.60 | -12.67% | |
| ₹45.45 | ₹47.90 | ₹38.94 | ₹46.49 | +2.29% | |
| ₹49.33 | ₹65.79 | ₹35.36 | ₹45.40 | -7.97% | |
| ₹62.61 | ₹62.61 | ₹40.79 | ₹46.99 | -24.95% | |
| ₹114.45 | ₹114.45 | ₹65.90 | ₹65.90 | -42.42% | |
| ₹119.95 | ₹144.40 | ₹115.15 | ₹119.10 | -0.71% | |
| ₹101.24 | ₹114.26 | ₹98.71 | ₹114.26 | +12.86% | |
| ₹69.59 | ₹99.26 | ₹68.20 | ₹99.26 | +42.64% | |
| ₹49.82 | ₹68.23 | ₹49.82 | ₹68.23 | +36.95% | |
| ₹28.47 | ₹48.85 | ₹28.22 | ₹48.85 | +71.58% | |
| ₹44.56 | ₹45.45 | ₹29.70 | ₹29.70 | -33.35% |
AI Research Briefing
Powered by Gemini · 2026-08-01
A promoterless trading shell with explosive paper receivables, zero cash generation, and executive flight.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The latest corporate filings show revolving-door leadership changes, including Whole-Time Director Kumar Anubhav Upadhyay resigning in February 2026 and Independent Director departures in March 2026. The board scheduled discussions on potential acquisitions and related party transactions in Q1 2026, but operational momentum remains dead in the water.
CORE STORY (THE REAL GAME)
This is not a pharmaceutical research or formulation company—it is a shell-like trading intermediary passing low-margin FMCG and tobacco inventory through its balance sheet. Formerly Rubra Medicaments, the business pivoted away from pharma formulations to general trading in 2022. The market treated this as a micro-cap pump vehicle in late 2025, but that narrative has completely collapsed under the weight of poor cash conversion.
- Board meeting updates in Q1 2026 flagged director resignations and undisclosed acquisition proposals.
- FII holding dropped by 2.12% as foreign investors exited the illiquid counter.
- Working capital inflated massively with ₹139.06 Cr in receivables against ₹0.13 Cr cash.
- Outcome or details regarding board-discussed acquisition/related party deals.
- Quarterly earnings demonstrating actual cash realization of the ₹139.06 Cr trade receivables.
- Operator-driven low-float circuit moves.
- Zero promoter equity holding (0.0%) indicating zero insider commitment.
- Severe micro-cap liquidity risk with extreme downside slippage on low volume.
- 5-year Free Cash Flow standing at ₹-28.32 Cr alongside ₹139.06 Cr tied up in receivables.
FII stake reduced by 2.12% to 8.59%, while DII holding remains at 0.0% and Promoters hold 0.0%. Smart money is actively exiting.
Broader Indian pharma sector benefits from government policy tailwinds, but Checkpoint operates as a low-margin trading proxy with zero direct sectoral benefit.
No major order wins found after live search; Q2 FY2026 trading revenue was reported at ₹108.59 Cr.
Extremely poor cash quality; 5-year FCF is negative at ₹-28.32 Cr.
High risk of continued capitulation as receivables fail to materialize into earnings and governance concerns persist.
Primary Thesis Risk
Receivable defaults leading to sudden balance sheet write-offs and complete illiquidity.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Checkpoint Trends Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Checkpoint Trends Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CHECKPOINT across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Excellent ROCE Performance (15.00%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 13.13 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (111664.00%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (310.88% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (172.77% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (172.77% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.29)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Margin Pressure Concerns (0.40%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-700.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Negative Free Cash Flow (₹-28.32 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Limited Institutional Interest (FII+DII: 8.59%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Checkpoint Trends Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Checkpoint Trends Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Checkpoint Trends LtdCheckpoint Tren...Selected✓ CHECKPOINT • 531099 | 51/100 | ₹33.46₹33 | ₹19.83₹19.83 | 13.13Average 13.1 Average | 12.69%Average 12.69% Average | 15.00%Good 15.00% Good | 0.29Excellent 0.3 Excellent | 172.77%Excellent 172.77% Excellent | 310.88%Excellent 310.88% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Checkpoint Trends Ltd PE Ratio History
Historical price-to-earnings ratio for CHECKPOINT — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.05 | ₹114.26 | 2285.2x |
| FY 2024 | ₹0.06 | ₹13.05 | 217.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Checkpoint Trends Ltd Quarterly Performance
Latest quarterly metrics for CHECKPOINT — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
111664.00%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-700.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
310.88%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
172.77%
Compounded annual net profit growth over 5 years
Checkpoint Trends Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CHECKPOINT — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Checkpoint Trends Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Checkpoint Trends Ltd (CHECKPOINT) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Checkpoint Trends Ltd
About CHECKPOINT (Checkpoint Trends Ltd)
Checkpoint Trends Ltd is a dynamic pharmaceutical enterprise carving a unique niche within the Indian healthcare landscape. While rooted in a foundational trading business, the com...pany's strategic vision extends beyond mere distribution. Checkpoint Trends is actively cultivating a portfolio of specialized pharmaceutical products, focusing on therapeutic areas with unmet needs and significant growth potential. Their approach involves identifying and sourcing innovative formulations, leveraging established distribution networks, and forging strategic alliances to bring cutting-edge treatments to market. Through meticulous market analysis and a commitment to quality, Checkpoint Trends is poised to become a trusted provider of specialized pharmaceuticals, offering valuable solutions to both healthcare professionals and patients. Central to Checkpoint Trends' operational philosophy is a commitment to providing comprehensive value beyond simply offering products. Recognizing the complexities of the pharmaceutical sector, the company offers a suite of management and consultancy services, drawing on its deep understanding of the Indian healthcare market. These services are designed to empower partner companies and healthcare providers, enabling them to navigate regulatory hurdles, optimize supply chains, and implement best practices in patient care. By combining its trading expertise with its advisory capabilities, Checkpoint Trends aims to foster a collaborative ecosystem within the pharmaceutical industry, contributing to the overall advancement of healthcare delivery and the improvement of patient outcomes. Originally established in 1991 as Rubra Medicaments Limited and rebranding to Checkpoint Trends Limited in May 2022, the company's evolution reflects its adaptability and forward-thinking approach. Headquartered in Mumbai, India, Checkpoint Trends benefits from its strategic location within one of the country's major pharmaceutical hubs. The company's enduring presence in the market provides a solid foundation for future expansion and innovation. By remaining agile and responsive to emerging trends, Checkpoint Trends is well-positioned to capitalize on the evolving demands of the Indian pharmaceutical market and solidify its position as a key player in the industry.
Company Details
Key Leadership
Latest News
CHECKPOINT Share Price: Frequently Asked Questions
What is the current share price of Checkpoint Trends Ltd?
Checkpoint Trends Ltd (CHECKPOINT) trades at ₹33.46 on NSE and BSE. Market cap ₹19.83 (Cr). Educational data only.
What is the P/E ratio of Checkpoint Trends Ltd?
Checkpoint Trends Ltd has a P/E of 13.13x vs industry average 34.89x.
What is the Bull Run score for Checkpoint Trends Ltd?
Checkpoint Trends Ltd has a Bull Run score of 51/100 based on 25+ financial parameters.
Does Checkpoint Trends Ltd pay dividends?
Checkpoint Trends Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Checkpoint Trends Ltd?
Checkpoint Trends Ltd has ROE of 12.69%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Checkpoint Trends Ltd?
Checkpoint Trends Ltd has debt-to-equity of 0.29.
Is Checkpoint Trends Ltd a good investment?
Bull Run gives Checkpoint Trends Ltd a score of 51/100. This is not investment advice — consult a SEBI-registered advisor.